Nektar Therapeutics
NKTR
$57.13
$2.284.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 28.26% | 30.95% | 24.34% | 56.91% | 42.69% |
| Total Depreciation and Amortization | -79.55% | -69.36% | -54.92% | -43.81% | -38.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -211.49% | -27,156.76% | -1,208.88% | -157.43% | -113.79% |
| Change in Net Operating Assets | -6,581.38% | -263.10% | 101.09% | 68.65% | 101.69% |
| Cash from Operations | -7.46% | -5.81% | 6.21% | 8.77% | 13.13% |
| Capital Expenditure | 50.88% | -89.89% | -122.92% | -69.71% | -9.30% |
| Sale of Property, Plant, and Equipment | -- | 5,151.89% | 5,151.89% | 5,151.89% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -106.07% | 23.77% | -12.45% | -43.49% | -32.18% |
| Cash from Investing | -41.20% | 81.43% | 41.26% | 2.15% | -38.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,046.81% | 823.53% | 269.70% | 293.33% | -61.16% |
| Repurchase of Common Stock | 100.00% | 100.00% | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -102.56% | -100.00% | -100.00% | -- | -- |
| Cash from Financing | 237.66% | -99.25% | -99.71% | 140,293.33% | 34,649.59% |
| Foreign Exchange rate Adjustments | 234.48% | 110.10% | -66.67% | -106.45% | -126.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.38% | 166.03% | 65.57% | 116.95% | 14.75% |